International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Neoteric advances in the role of hematopoietic stem cell transplantation in AML: A complete review

Article Information

Volume / Issue2 / 4 (October-December 2021)
Pages28-33
AccessOpen Access

Publication Timeline

  • Received01 October 2021
  • Accepted16 October 2021

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Hematopoietic stem cell transplantation (HSCT) remains an effective treatment modality for curative post-remission therapy for AML patients. Recent scientific and clinical advances in supportive care, donor selection, and conditioning regimens have decreased transplant-related mortality, an extension of HSCT to elderly patients, and improvements in survival rate. The molecular pathology of AML is studied extensively in the past decade provided with explosive information. Still, relapse remains the most important cause for failure of the treatment. It is expected that a majority of eligible patients can receive HSCT in first complete remission (CR1) by early identification of patients at a high risk of relapse. Newer conditioning regimens have been explored to improve transplant outcomes in AML. In this paper, we review recent advances in HSCT for high-intermediate and low-risk AML in CR1, for relapsed AML and the older patients, and summarize the latest approaches and provide future direction in the transplantation for patients with AML.

References

  1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. New England Journal of Medicine. 2015; 373(12):1136-52. doi: 10.1056/NEJMra1406184.PubMed PMID: 26376137. [Google Scholar][Crossref]
  2. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004, 98-117. Epub 2004/11/25. doi: 10.1182/asheducation-2004.1.98. PubMed PMID: 15561679. [Google Scholar][Crossref]
  3. Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica. 2014; 99(11):1663-70. Epub 2014/11/25. doi: 10.3324/haematol.2014.114611.PubMed PMID: 25420282; PubMed Central PMCID: PMCPMC4222459. [Google Scholar][Crossref]
  4. Singh AK, McGuirk JP. Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview. Cancer Res. 2016; 76(22):6445-51. Epub 2016/10/28. doi: 10.1158/0008-5472.CAN-16-1311. PubMed PMID: 27784742. [Google Scholar][Crossref]
  5. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011; 117(8):2307-18. Epub 2010/11/26. doi: 10.1182/blood-2010-10-265603. PubMed PMID: 21098397. [Google Scholar][Crossref]
  6. Valcarcel D, Martino R, Pinana JL, Sierra J. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. Curr Opin Oncol. 2009; 21(1):S35-7. Epub 2009/ 07/09. doi: 10.1097/01.cco.0000357474.66035.9b. PubMed PMID: 19561412. [Google Scholar][Crossref]
  7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990; 75(3):555-62. Epub 1990/02/01. PubMed PMID: 2297567. [Google Scholar][Crossref]
  8. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, et al. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018; 2(17):2254-61. Epub 2018/09/13. doi: 10.1182/bloodadvances.2018021899.PubMed PMID: 30206098; PubMed Central PMCID: PMCPMC6134218. [Google Scholar][Crossref]
  9. Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML). American cancer society. 1, 1-9. [Google Scholar][Crossref]
  10. Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, et al. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. Ann Hematol. 2017; 96(2):289-97. Epub 2016/11/14. doi: 10.1007/s00277-016-2872-y. PubMed PMID: 27838773. [Google Scholar][Crossref]
  11. De Lima M. New approaches to transplantation in acute myelogenous leukemia. Hematology Am Soc Hematol Educ Program. 2015; 2015:596-604. Epub 2015/12/08. doi: 10.1182/asheducation-2015.1.596. PubMed PMID: 26637777. [Google Scholar][Crossref]
  12. Stein EM, Tallman MS. Remission induction in acute myeloid leukemia. Int J Hematol. 2012; 96(2):164-70. Epub 2012/07/14. doi: 10.1007/s12185-012-1121-y.PubMed PMID: 22791508; PubMed Central PMCID: PMCPMC4052975. [Google Scholar][Crossref]
  13. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301(22):2349-61. Epub 2009/06/11. doi: 10.1001/jama.2009.813. PubMed PMID: 19509382; PubMed Central PMCID: PMCPMC3163846. [Google Scholar][Crossref]
  14. Kassim AA, Savani BN. Hematopoietic stem cell transplantation for acute myeloid leukemia: A review. Hematol Oncol Stem Cell Ther. 2017; 10(4):245-51. Epub 2017/07/01. doi: 10.1016/j.hemonc.2017.05.021.PubMed PMID: 28666104. [Google Scholar][Crossref]
  15. Acute Myeloid Leukemia. National comprehensive cancer network, Clinical Practice Guidelines in Oncology, 2021, 3(March 2). International Journal of Medical and all body Health Research www.allmedicaljournal.com 32 [Google Scholar][Crossref]
  16. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005; 103(8):1652-8. Epub 2005/03/03. doi: 10.1002/cncr.20945. PubMed PMID: 15742336. [Google Scholar][Crossref]
  17. Ringden O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Intern Med. 2012; 272(5):472-83. Epub 2012/04/24. doi: 10.1111/j.1365-2796.2012.02547.x. PubMed PMID: 22519980. [Google Scholar][Crossref]
  18. Vydra J, Salek C, Schwarz J, Zak P, Novak J, Petecukova V, et al. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. Clin Lymphoma Myeloma Leuk. 2018; 18(2):106-13. Epub 2018/01/01. doi: 10.1016/j.clml.2017.11.011. PubMed PMID: 29289481. [Google Scholar][Crossref]
  19. Ostgard LSG, Lund JL, Norgaard JM, Norgaard M, Medeiros BC, Nielsen B, et al. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study. Biol Blood Marrow Transplant. 2018; 24(2):314-23. Epub 2017/10/21. doi: 10.1016/j.bbmt.2017.10.019. PubMed PMID: 29051022. [Google Scholar][Crossref]
  20. Li D, Wang L, Zhu H, Dou L, Liu D, Fu L, et al. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS One. 2015; 10(7):e0132620. Epub 2015/07/22. doi: 10.1371/journal.pone.0132620. PubMed PMID: 26197471; PubMed Central PMCID: PMCPMC4510363. [Google Scholar][Crossref]
  21. Chang YJ, Huang XJ. Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplant. 2014; 49(7):873-9. Epub 2014/02/26. doi: 10.1038/bmt.2014.19. PubMed PMID: 24566712. [Google Scholar][Crossref]
  22. Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, et al. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017; 102(11):1810-22. Epub 2017/09/09. doi: 10.3324/haematol.2017.176107.PubMed PMID: 28883081; PubMed Central PMCID: PMCPMC5664385. [Google Scholar][Crossref]
  23. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013; 119(5):978-85. Epub 2012/10/26. doi: 10.1002/cncr.27761. PubMed PMID: 23097265. [Google Scholar][Crossref]
  24. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. conditioning including antithymocyte globulin followed by unmanipulated HLA -mismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006; 107(8):3065-73. Epub 2005/12/29. doi: 10.1182/blood-2005-05-2146.PubMed PMID: 16380454. [Google Scholar][Crossref]
  25. Horwitz ME, Wease S, Blackwell B, Valcarcel D, Frassoni F, Boelens JJ, et al. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. J Clin Oncol. 2019; 37(5):367-74. Epub 2018/12/14. doi: 10.1200/jco.18.00053. PubMed PMID: 30523748; PubMed Central PMCID: PMCPMC6368416. [Google Scholar][Crossref]
  26. Van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019; 3(12):1858-67. Epub 2019/06/21. doi: 10.1182/bloodadvances.2019000200. PubMed PMID: 31217161; PubMed Central PMCID: PMCPMC6595267 grant from Miltenyi Biotec. The remaining authors declare no competing financial interests. [Google Scholar][Crossref]
  27. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016; 127(1):62-70. Epub 2015/12/15. doi: 10.1182/blood-2015-07-604546. PubMed PMID: 26660427. [Google Scholar][Crossref]
  28. Medeiros BC. Is there a standard of care for relapsed AML? Best Pract Res Clin Haematol. 2018; 31(4):384-6. Epub 2018/11/24. doi: 10.1016/j.beha.2018.09.006.PubMed PMID: 30466752. [Google Scholar][Crossref]
  29. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011; 29(5):487-94. Epub 2011/01/12. doi: 10.1200/jco.2010.30.1820. PubMed PMID: 21220605. [Google Scholar][Crossref]
  30. Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016; 51(11):1431-8. Epub 2016/11/03. doi: 10.1038/bmt.2016.167. PubMed PMID: 27295272. [Google Scholar][Crossref]
  31. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol. 2005; 128(1):59-65. Epub 2004/12/21. doi: 10.1111/j.1365-2141.2004.05282.x. PubMed PMID: 15606550. [Google Scholar][Crossref]
  32. Gabriel N. Mannis MD TGMIM, Lloyd E. Damon MD, Aaron, C. Logan MD P, Rebecca L. Olin MD. Long-Term Outcomes of Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with Autologous Hematopoietic Cell Transplant in First Complete Remission. Leukemia & Lymphoma, 2015. [Google Scholar][Crossref]
  33. Zuanelli Brambilla C, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, et al. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Transplant Cell Ther, 2021. Epub 2021/05/26. doi: 10.1016/j.jtct.2021.05.011. PubMed PMID: 34033977. [Google Scholar][Crossref]
  34. Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda International Journal of Medical and all body Health Research www.allmedicaljournal.com 33 T, Shingai N, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2021; 56(5):1126-33. Epub 2020/12/04. doi: 10.1038/s41409-020-01163-z. PubMed PMID: 33268829. [Google Scholar][Crossref]
  35. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021; 27(1):6-20. Epub 2020/09/24. doi: 10.1016/j.bbmt.2020.09.020. PubMed PMID: 32966881. [Google Scholar][Crossref]
  36. Getta BM, Roshal M, Zheng J, Park JH, Stein EM, Levine R, et al. Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. Biol Blood Marrow Transplant. 2017; 23(11):1879-86. Epub 2017/07/12. doi: 10.1016/j.bbmt.2017.06.026. PubMed PMID: 28694182; PubMed Central PMCID: PMCPMC5682215. [Google Scholar][Crossref]
  37. Lim ABM, Curley C, Fong CY, Bilmon I, Beligaswatte A, Purtill D, et al. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. Intern Med J. 2018; 48(3):276-85. Epub 2017/06/20. doi: 10.1111/imj.13522. PubMed PMID: 28628276. [Google Scholar][Crossref]
  38. Lipof JJ, Loh KP, O'Dwyer K, Liesveld JL. Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. Cancers (Basel), 2018, 10(6). Epub 2018/06/06. doi: 10.3390/cancers10060179.PubMed PMID: 29866998; PubMed Central PMCID: PMCPMC6025016. [Google Scholar][Crossref]
  39. He F, Cao Q, Lazaryan A, Brunstein C, Holtan S, Warlick E, et al. Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biol Blood Marrow Transplant. 2017; 23(9):1485-90. Epub 2017/05/20. doi: 10.1016/j.bbmt.2017.05.012. PubMed PMID: 28522345; PubMed Central PMCID: PMCPMC5586072. [Google Scholar][Crossref]
  40. Lazarevic VL. Acute myeloid leukaemia in patients we judge as being older and/or unfit. J Intern Med, 2021. Epub 2021/03/30. doi: 10.1111/joim.13293. PubMed PMID: 33780573. [Google Scholar][Crossref]
  41. Duarte RF, Sanchez-Ortega I. HSCT in Elderly Patients. In: th, Carreras E, Dufour C, Mohty M, Kroger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Cham (CH), 2019, 499-503. [Google Scholar][Crossref]
  42. Del Galy AS, Marouf A, Raffoux E, Robin M, Michonneau D, Sebert M, et al. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia. 2021; 35(1):225-8. Epub 2020/08/01. doi: 10.1038/s41375-020-1004-9. PubMed PMID: 32733010. [Google Scholar][Crossref]

How to Cite

K, N. S. J., & Ashif, M. (2021). Neoteric advances in the role of hematopoietic stem cell transplantation in AML: A complete review. International Journal of Medical and All Body Health Research, 2(4), 28-33.

K, Nuseba Shehla Jeelani, and Mohammed Ashif. "Neoteric advances in the role of hematopoietic stem cell transplantation in AML: A complete review." International Journal of Medical and All Body Health Research, vol. 2, no. 4, 2021, pp. 28-33.

K, N. S. J. and Ashif, M. (2021) 'Neoteric advances in the role of hematopoietic stem cell transplantation in AML: A complete review', International Journal of Medical and All Body Health Research, 2(4), pp. 28-33.

K NSJ, Ashif M. Neoteric advances in the role of hematopoietic stem cell transplantation in AML: A complete review. International Journal of Medical and All Body Health Research. 2021;2(4):28-33.

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.